Regulatory Decisions and Manic Induction Reports

Bradley explains FDA denial for depression indication, allowed labeling for anxiety with depression, and reports of alprazolam-induced mania.

Play episode from 11:24

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!